Mixed Outlook for Adagene and Lantheus as FDA Extends OCTEVY Review Timeline

Investors are closely monitoring Adagene’s lead asset, ADG126, with pivotal clinical updates expected at the AACR 2026 conference to validate its position in immuno-oncology. Meanwhile, Lantheus Holdings faced a three-month FDA PDUFA extension for its drug OCTEVY, delaying the potential approval and launch until June 2026. This extension is reportedly procedural and tied to manufacturing reviews rather than concerns over the drug's efficacy or safety profile. While OCTEVY is expected to bolster Lantheus's strategic pivot toward PET radiodiagnostics, analysts suggest it may not be sufficient to restore double-digit growth on its own. Simultaneously, Adagene continues to leverage strategic partnerships with Sanofi and Incyte to strengthen its financial outlook. Market participants are now recalibrating expectations based on these updated regulatory and clinical timelines for both biotech players.